表紙
市場調查報告書

CountryFocus:日本的醫療、規定、醫療費償付制度狀況

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan

出版商 GlobalData 商品編碼 275366
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
CountryFocus:日本的醫療、規定、醫療費償付制度狀況 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan
出版日期: 2019年04月01日內容資訊: 英文 131 Pages
簡介

日本今後,由於法規改革預計在醫藥品的認證過程進行迅速化、效率化。因此,世界各國的大型製藥企業在日本國內設立研究開發 (R&D) 中心,投高額的資金打算開拓市場。

本報告提供日本的醫療相關市場趨勢,及醫療費償付制度及相關法規、制度相關分析,醫藥品產業、醫療設備產業的整體結構、趨勢,醫療費償付制度等的制度的概要、趨勢,醫療法規當局和各種法規概要,日本經濟、社會相關宏觀指標 (人口結構,醫療基礎設施等) 的資訊彙整,為您概述為以下內容。

目錄

  • 摘要整理
  • 醫藥品市場概要
  • 醫療設備市場概要
  • 資本交易分析
  • 波特的五力分析
  • 市場進入
  • 日本國內的醫療環境
  • 市場機會與課題

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC0077CHR

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Japan",. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Japan. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Japan. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

In 2010, the Japanese pharmaceutical market was worth $67.5B, which decreased to an estimated $61.8B in 2017 at a negative Compound Annual Growth Rate (CAGR) of 2%. The Japanese medical devices market was valued at $48.3B in 2015, which increased to $52.2B in 2017. The market is expected to grow at a CAGR of 4.1% from $54.5B in 2018 to $59.4B in 2020. Regulatory reforms have led to faster and more efficient drug approval processes. This has led to international pharmaceutical companies establishing R&D centers and increasing their investments in Japan.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the Japan, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Daiichi Sankyo, Astellas, Roche, Takeda, and Otsuka) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Terumo and Fujitsu)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Japan
  • Porter's five forces analysis for pharmaceutical and medical devices market of Japan
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunitiesand challenges to growth in the Japanese healthcare market.

Reasons to buy

The report provides information on the healthcare, regulatory, and reimbursement landscape in the Japan, and includes -

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Daiichi Sankyo, Astellas, Roche, Takeda, and Otsuka) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, Abbott, Roche, Terumo and Fujitsu)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of Japan
  • Porter's five forces analysis for pharmaceutical and medical devices market of Japan
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Japanese healthcare market.

Table of Contents

  • Executive Summary
  • Overview of Pharmaceutical Market
  • Overview of Medical Device Market
  • Deals Analysis
  • Porter's Five Forces Model
  • Market Access
  • Country Healthcare Landscape
  • Opportunities and Challenges

Appendix

List of Tables

  • Table 1: Approved Biosimilars, Japan, 2018
  • Table 2: Top Five Therapeutic Areas by Drug Production Value ($B), Japan, 2017
  • Table 3: Ophthalmic Devices Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2015
  • Table 4: Nephrology and Urology Devices Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2016
  • Table 5: In Vitro Diagnostics Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2017
  • Table 6: Diagnostic Imaging Market, Japan, Revenue ($B), 2015-2022
  • Table 7: Hospital Supplies Market, Japan, Revenue ($M) and Market Share (%) of Major Companies, 2017
  • Table 8: Medical Device Classification, Japan, 2016
  • Table 9: Patent Fees, Japan, 2019
  • Table 10: Trademark Fees, Japan, 2019
  • Table 11: Trade Fairs, Japan, 2019

List of Figures

  • Figure 1: Pharmaceutical Market, Japan, Revenue ($B), 2010-2017
  • Figure 2: Medical Device Market, Japan, Revenue ($B), 2015-2020
  • Figure 3: Country Profile, Japan, 2018
  • Figure 4: Pharmaceutical Market, Japan, Revenue ($B), 2010-2017
  • Figure 5: Pharmaceutical Market, Japan, Revenue Forecast ($B), 2018-2022
  • Figure 6: Pharmaceutical Exports ($B), Japan, 2010-2018
  • Figure 7: Top Export Partners, Japan, 2018
  • Figure 8: Pharmaceutical Imports ($B), Japan, 2010-2018
  • Figure 9: Top Import Partners, Japan, 2018
  • Figure 10: Pharmaceutical Supply Chain, Japan, 2019
  • Figure 11: Generic Drugs Market (% share), Japan, 2009-2017
  • Figure 12: Major Approved Biopharmaceuticals in Japan, Japan, 2016
  • Figure 13: Breakdown of Approved Biopharmaceuticals, Japan, 2016
  • Figure 14: Top 5 Therapeutic Areas by Annual Turnover ($B), Japan, 2017
  • Figure 15: Pharmaceutical Market, Major Players, 2017
  • Figure 16: Medical Device Market, Japan, Revenue ($B), 2015-2020
  • Figure 17: Medical Device Market, Japan, Revenue Forecast ($B), 2021-2025
  • Figure 18: Medical Device Market, Japan, Revenue by Segment ($B), 2018
  • Figure 19: Ophthalmic Devices Market, Japan, Revenue ($B), 2015-2022
  • Figure 20: Ophthalmic Devices Market, Japan, Market Share of Major Players (%), 2015
  • Figure 21: Nephrology and Urology Devices Market, Japan, Revenue ($B), 2015-2022
  • Figure 22: Nephrology and Urology Devices Market, Japan, Market Share of Major Companies (%), 2016
  • Figure 23: In Vitro Diagnostics Market, Japan, Revenue ($B), 2015-2022
  • Figure 24: In Vitro Diagnostics Market, Japan, Market Share of Major Players (%), 2017
  • Figure 25: Diagnostic Imaging Market, Japan, Revenue ($B), 2015-2022
  • Figure 26: Diagnostic Imaging Market, Japan, Market Share of Major Players (%), 2016
  • Figure 27: Hospital Supplies Market, Japan, Revenue ($B), 2015-2022
  • Figure 28: Hospital Supplies Market, Japan, Market Share of Major Players (%), 2017
  • Figure 29: Diagnostic Market, Japan, Revenue ($B), 2015-2020
  • Figure 30: Diagnostic Market, Japan, Revenue ($B), 2021-2025
  • Figure 31: Medical Device Market, Japan, Revenue ($B) of Major Companies, 2017
  • Figure 32: Deal Value and Deal Count, Pharmaceutical Market, Japan, 2018-2019
  • Figure 33: Deal Value and Deal Count Quarterly, Pharmaceutical Market, Japan, 2018-2019
  • Figure 34: Deal Value and Deal Count Sub-Types, Pharmaceutical Market, Japan, 2018-2019
  • Figure 35: Top Five Therapy Areas by Deal Value, Pharmaceutical Market, Japan, 2018-2019
  • Figure 36: Top Five Therapy Areas by Deal Number, Pharmaceutical Market, Japan, 2018-2019
  • Figure 37: M&A Deals by Therapy Area, Pharmaceutical Market, Japan, 2018-2019 (by value and by number)
  • Figure 38: Venture Financing Deals by Therapy Area, Pharmaceutical Market Japan, 2018-2019(by value and by number)
  • Figure 39: Medical Device Market Deals (by deal value, $M), Japan, 2018
  • Figure 40: Medical Device Market Deals (by deal count), Japan, 2018
  • Figure 41: Medical Device Market Deals Share (by deal count), Japan, 2018
  • Figure 42: Medical Device Market Deals Share (by deal value), Japan, 2017-2018
  • Figure 43: Medical Device Market Deals, Japan, Top Therapy Area by Deal Value, 2018
  • Figure 44: Medical Device Market Deals, Japan, Top Therapy Area by Deal Number, 2018
  • Figure 45: Medical Device Market Deals, Japan, M&A Deals by Therapy Area, 2018
  • Figure 46: Medical Device Market Deals, Japan, Venture Financing Deals by Therapy Area, 2018
  • Figure 47: Medical Device Market Deals, Japan, Private Equity Deals by Therapy Area, 2018
  • Figure 48: Organization of the Health System, Japan, 2018
  • Figure 49: Reimbursement Pricing for New Drugs, Japan, 2018
  • Figure 50: Public Insurance Schemes, Japan, 2016
  • Figure 51: Public Insurance Schemes, People Insured by Scheme (%), Japan, 2016
  • Figure 52: Financial flow based on insurance flows, Japan, 2016
  • Figure 53: Cross-subsidy mechanism, Japan, 2017
  • Figure 54: Out-of-Pocket Expenditure (% of total expenditure on health), Japan, 2010-2017
  • Figure 55: Annual Rate of Change (%), Medicines and health fortification Price Index, Japan, 2010-2018
  • Figure 56: Types of Premiums, Japan, 2016
  • Figure 57: Pricing Policies, Japan, 2017
  • Figure 58: Ministry of Health, Labour and Welfare, Organization Chart, 2018
  • Figure 59: Organization of PSEHB and PMDA, Japan, 2018
  • Figure 60: Drug Approval Process, Japan, 2018
  • Figure 61: Drug Approval Process Timeline, Japan, 2018
  • Figure 62: Patent Approval Process, Japan, 2016
  • Figure 63: Trademark Process Timeline, Japan, 2017
  • Figure 64: Clinical Trial Notification Process, Japan, 2018
  • Figure 65: Layout of Package Insert Based on Revised Guidelines for Preparation, Japan, 2018
  • Figure 66: Health Care 2035, Japan, 2019
  • Figure 67: Health Care 2035, Japan, 2019
  • Figure 68: Hospitals (number), Japan, 2010-2017
Back to Top